Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
Marvel Biosciences has selected Australia's CMAX Clinical Research as the Phase I site for its lead drug candidate MB-204, moving the asset toward first-in-human evaluation. The planned program begins with a single ascending dose study assessing safety, tolerability, pharmacokinetics, biomarkers and cognitive endpoints, with trial initiation still contingent on regulatory and ethics approvals.
Key figures
- Drug Name
- MB-204
- Phase Of Trial
- Phase I
- Cmax bed capacity
- 78
- Cmax studies per year
- >40
- Cmax studies conducted
- >600
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.